Nipfilan^®

Nipfilan^® contains the active substance nintedanib, a medicine belonging to the class of so-called tyrosine kinase inhibitors, and is used for the treatment of the following diseases:

Idiopathic pulmonary fibrosis (IPF) in adults

IPF is a condition in which the tissue in your lungs becomes thickened, stiff and scarred over time. The scarring results in a reduction in the ability to transfer oxygen from the lungs into the bloodstream and it becomes difficult to breathe deeply. This medicine helps to reduce further scarring and stiffening of the lungs.

Other chronic progressive fibrosing interstitial lung diseases (ILDs) in adults

Besides IPF, there are other conditions in which the tissue in your lungs becomes thickened, stiff, and scarred over time (lung fibrosis) and keeps worsening (progressive). Examples of these conditions are hypersensitivity pneumonitis, autoimmune ILDs (e.g. rheumatoid arthritis associated ILD), idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. This medicine helps to reduce further scarring and stiffening of the lungs.

Clinically significant, progressive fibrosing interstitial lung diseases (ILDs) in children and adolescents from 6 to 17 years old

Lung fibrosis may occur in patients with Childhood Interstitial Lung Disease (chILD). When this is the case, the tissue in the lungs of children and adolescents becomes thickened, stiff, and scarred over time. Nipfilan helps to reduce further scarring and stiffening of the lungs.

Systemic sclerosis associated interstitial lung disease (SSc-ILD) in adults, adolescents and children aged 6 years and older

Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic autoimmune disease that affects connective tissue in many parts of the body. SSc causes fibrosis (scarring and stiffening) of the skin and other internal organs such as the lungs. When the lungs are affected by fibrosis, it is called interstitial lung disease (ILD), and so the condition is called SSc-ILD. Fibrosis in the lungs reduces the ability to transfer oxygen into the bloodstream, and breathing capacity is reduced. This medicine helps to prevent further scarring and stiffening of the lung tissue.